Feasibility Study of an Innovative Medical Device for Sampling the Contents of the Small Intestine.

University Hospital, Grenoble16 enrolled

Overview

For the first time in the world, the objective of this study is to evaluate on healthy volunteers, an innovative medical device for the capture of intestinal liquid.This medical device is not yet CE marked.

This medical device consists of a standard pill made of 3 capsules for the collection of intestinal microbiota. The pill is ingested by the volunteer and multi-omics analysis will be performed on intestinal fluid samples from the capsules and also on faeces. First in man, involving a medical device, prospective, monocentric, not randomized, not controlled and open-label study.

Study Type

INTERVENTIONAL

Allocation

Purpose

DEVICE_FEASIBILITY

Masking

NONE

Enrollment

Conditions

Healthy Volunteers

Interventions

Innovative medical device for sampling small intestine contentDEVICE

Ingestion of the medical device by the volunteer

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Able to understand the study and the associated instructions * Aged ≥18 years and ≤65 years * Fasting with water and food for at least 10 hours * BMI between ≥20 and ≤30 kg/m². * Transit evaluated at 1 to 3 bowel movements/day * Maintain regular physical activity and eating habits for the duration of the study * Affiliated with a social security plan * Have a freezer in their home and at work, if applicable * Volunteer staying in the Isère department during the collection of the faeces (from 96 hours to 15 days max) * Having signed the informed and collection consent Exclusion Criteria: Subject : * with medical treatment (except oral contraception and/or probiotics and related products) * with lactose and fructose intolerance * with of gastroparesis * who had a colonoscopy preparation up to 1 month prior to inclusion * in the exclusion period of another clinical investigation, * who receive more than 4500 euros of compensation due to his participation in other biomedical research in the 12 months preceding this study * who cannot be contacted in case of emergency * who has taken during the 15 days prior to inclusion and/or is scheduled to take the following treatments during the study: antidepressants, anxiolytics, antiparkinsonian agents, neuroleptics, antibiotics and prebiotics * who has taken during the previous 7 days: at least once a treatment for irritable bowel syndrome (antispasmodics,..) or for constipation (laxative) or for diarrhea * with a known food allergy * who have to undergo colon surgery * with intestinal obstruction history * with hepatic, cardiac, congenital or renal comorbidity * with long-standing diabetes * with an inflammatory disease of the digestive tract, a history of digestive surgery * who have been treated with radiotherapy or who have taken anti-inflammatory drugs for a long time * with gastric fullness * with known or suspected obstruction of the gastrointestinal tract (including known inflammatory bowel or intestinal diverticula) * with presence of swallowing disorders or Zencker's diverticulum * with nausea, deviated nasal septum * with contraindications to esophageal tube placement (chronic esophageal pathology) * drug or alcohol abuse (3 units for men and 2 units for women according to WHO criteria) * with a known allergy to silicone or to iodine * refusing medical imaging or surgery (in case of non-recovery of the capsule) * protected person concerned by the articles L1121-5 to L1121-8 of the Public Health Code * absence of highly effective contraception for women with childbearing capacity until the end of the cycle following the end of participation in the trial

Locations (1)

University Hospital Grenoble Alpes

Grenoble, France

Outcomes

Primary Outcomes

Demonstrate the absence of adverse events (safety of the medical device) and that the device is analyzable (performance of the medical device).

Safety is assessed with the absence of grade \>3 adverse events. Performance is assessed by the presence of at least one capsule found in the stool with a satisfactory visual condition of capsule and with a sufficient volume of its contents within 96 hours after ingestion. The primary objective of this study is met if safety and performance are achieved for at least 12 of 15 volunteers.